whether it is for the small or large intestine might be related to the formulation and/or coating so that it targets different areas. I think Uceris is a time-release formula, but do not see too many other details. I did find a poster at a gastro conferene where the success rate among patients who had not gotten remission with other therapies was 25% (althought they say 33% had complete resolution of symptioms, which IMO is just as good).
"CONCLUSIONS: 25% of patients achieved robust clinical and endoscopic remission
and 33.3% achieved complete symptom resolution with 8 weeks of open label BMMX
9 mg after initial treatment allocation in a placebo controlled trial failed to
induce remission. An additional 8 week course of B-MMX 9 mg in patients previously
exposed to B-MMX treatment does not significantly affect MPC. Therapy
with B-MMX for up to 16 consecutive weeks was safe and well-tolerated"
http://onlinelibrary.wiley.com/doi/10.1002/ibd.21939/pdf (p. 30)
------
While both articles are welcome news, these do seem to be medications that dampen inflamation, and would need to be taken at maintence doses - in other words do not directly correct the underlying dysregulation in the immune system